Atom Investors’s iBio IBIO Stock Holding History

Atom Investors’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-133	Closed	-$37K	–	258
2021 Q4	$37K	Buy	+133	New	+$50.7K	0.01%	255
2021 Q2	–	Sell	-32	Closed	-$25K	–	282
2021 Q1	$25K	Sell	32 -38	-54%	-$33.1K	﹤0.01%	237
2020 Q4	$37K	Hold	70	–	–	﹤0.01%	359
2020 Q3	$71K	Buy	+70	New	+$101K	0.01%	489

Other funds holding IBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Atom Investors's IBIO Position: Q1 2022 in Review

Atom Investors sold out of iBio (IBIO) in Q1 2022, closing a stake of 133 shares — an estimated $37K sold.

Atom Investors first reported a position in IBIO in Q3 2020 and held it in 4 quarters. The position peaked at $71K in Q3 2020. 70 funds tracked by Wall St. Rank hold IBIO as of Q1 2022.

Atom Investors reported no remaining iBio position as of Q1 2022 after selling out during the quarter.
Atom Investors sold 133 iBio shares in Q1 2022, an estimated $37K.
Atom Investors first reported a position in iBio in Q3 2020 and held it in 4 quarters.
Atom Investors's iBio position peaked at $71K in Q3 2020.
70 funds tracked by Wall St. Rank held iBio as of Q1 2022.

Based on Atom Investors's 13F filing for Q1 2022, filed 16 May 2022.